Abstract
After a 12-year hiatus, military recruit training centers resumed administration of adenovirus type 4 and type 7 vaccine, live, oral (adenovirus vaccine) to trainees beginning in October of 2011. Subsequently, rates of febrile respiratory illnesses (FRI) and adenovirus isolations markedly declined. These findings are consistent with those of a placebo-controlled efficacy trial conducted prior to the vaccine's licensure by the U.S. Food and Drug Administration. Continued surveillance will clarify the longer term impact of vaccine use.
MeSH terms
-
Adenovirus Infections, Human / epidemiology
-
Adenovirus Infections, Human / immunology
-
Adenovirus Infections, Human / prevention & control*
-
Adenovirus Infections, Human / virology
-
Adenoviruses, Human*
-
Humans
-
Military Medicine*
-
Military Personnel
-
Population Surveillance
-
Program Development
-
Public Health
-
Respiratory Tract Infections / epidemiology
-
Respiratory Tract Infections / immunology
-
Respiratory Tract Infections / prevention & control*
-
Respiratory Tract Infections / virology
-
Time Factors
-
United States / epidemiology
-
Viral Vaccines*